Skip to main content
. 2022 Sep 20;328(11):1073–1084. doi: 10.1001/jama.2022.15632

Figure 3. Representative Photos of Patients Treated With Roflumilast Cream, 0.3%, Over Time in DERMIS-1 and DERMIS-2.

Figure 3.

IGA indicates Investigator Global Assessment; I-IGA, intertriginous IGA. IGA was measured based on whole-body involvement using a 5-point scale ranging from none (0) to severe (4). See eTable 1 in Supplement 5 for details of the scale. Images show an area of the whole-body measurement.